Lung Cancer Online
Home Care Support Info Treatment Effects Tests Surviving Sites MedLit

 home > treatment > agents & regimens > Sorafenib (Nexavar, BAY 43-9006)

Sorafenib (Nexavar, BAY 43-9006) : Bayer/Onyx : Oral cystostatic Raf kinase inhibitor

Sorafenib (Nexavar, BAY 43-9006) - Recent MEDLINE Abstracts (PubMed)

Sorafenib (Nexavar, BAY 43-9006)- Clinical Trials (ClinicalTrials.com)


 

Feedback / Queries Disclaimer Advocacy - You Can Help

Copyright © 1999-2006, Lung Cancer Online Foundation
Last modified: 26-Apr-2011
Karen Parles, MLS Editor